SIRPA and neoplasm: Recent Phase 1 clinical trials attempting to convert protumorigenic macrophages to anti-tumorigenic macrophages by blocking the CD47-SIRPα axis, for example, and making macrophages less immunosuppressive and more phagocytic of tumor cells themselves, have shown promise [12].